pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell
Samsung Bioepis
Samsung Bioepis NL B.V.
Samsung Bioepis is a pharma organization headquartered in KR. Primary therapeutic focus areas include Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach, Dyspepsia, Depression. NovaPharmaNews links 24 c
Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Yeonsu-gu, Incheon 21987, KR
- Founded
- 2012
- Employees
- 1,589
- Programs
- 24
- Drugs
- 34
- Patents
- 0
Intermittent hepatic inflow occlusion (IHIO)
Phase 3 · other · End Stage Liver Disease
Intermittent hepatic inflow occlusion (IHIO) for End Stage Liver Disease is a Phase 3 program (other) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Internal code 2007-09-096
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Samsung Bioepis NL B.V.
- Phase
- Phase 3
- Modality
- other
- Indication
- End Stage Liver Disease
- Status
- active
- Trials
- 1